Author: OurCrowd

[BrightInsight in GlobeNewswire] BrightInsight to showcase key updates to its BrightInsight platform and disease management solution at HLTH 2023

Oct 4, 2023 |

SAN JOSE, Calif. and LAS VEGAS, Oct. 04, 2023 (GLOBE NEWSWIRE) — BrightInsight, Inc., provider of the leading global platform for biopharma and medtech digital health solutions, announced today that it will showcase the latest technical enhancements to the BrightInsight® Platform and Disease Management Solution at the HLTH conference taking place October 8–11, 2023, in Las Vegas. Since initially launching the BrightInsight Platform in 2018, the company has invested over $100M in its underlying infrastructure – which allows it to deliver industry-leading scalability, functionality, configurability, speed, compliance and global availability. Read...

Read More

[ThetaRay in BusinessWire] UK Fintech Gemba chooses ThetaRay for its AML Program to support global growth

Oct 3, 2023 |

LONDON & NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–Gemba Finance, a leading provider of innovative banking and financial management solutions, and ThetaRay, the leader in next-generation AI-powered trusted global payments, announced today the implementation of ThetaRay’s AI-powered transaction monitoring technology, SONAR, to power Gemba’s growth, while reducing regulatory exposure which frequently hampers growth at financial institutions. Read more...

Read More

[OncoHost in PR Newswire] OncoHost’s PROphet® Platform to support Henlius US-Based Phase III Trial for patients with extensive-stage small cell lung cancer

Oct 3, 2023 |

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ — OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost’s PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin – etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Read...

Read More